Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Double Blind Placebo Controlled 12 Week Trial of Methotrexate Added to Treatment As Usual in Early Schizophrenia

NCT02074319 is registered in ClinicalTrials.gov with Pakistan Institute of Living and Learning as lead sponsor.

NCT NCT02074319
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02074319 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Double Blind Placebo Controlled 12 Week Trial of Methotrexate Added to Treatment As Usual in Early Schizophrenia
Lead sponsor
Pakistan Institute of Living and Learning
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2013
Completion date
August 31, 2015
Enrollment
92 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

schizoaffective disorder, schizophrenia, schizophreniform disorder